The Nucleic Acid Vaccine Branch of China Vaccine Industry Association-The Sixth National Nucleic Acid Vaccine Conference was held in Suzhou from September 17 to 20, 2022. The theme was "Nucleic Acid Vaccines Create the Future". Microfluidic Nano, as the sponsor of the conference and a partner of one of the organizers, participated in the conference and demonstrated the microfluidic nanohomogenizer, microfluidic synthesizer, Microfluidic nanometer particle size detector and other equipment and solutions to related problems.

Chairman of the Academic Committee of the Conference: Wang Bin, Jing Jing, Tan Wenjie, Sun Shuhan, Chen Ze, Secretary-General of the InBev Organizing Committee: Liu Xiaoyan

Organizer: Nucleic Acid Vaccine Branch of China Vaccine Industry Association

Organizer: Aidi Weixin Bio, Aibo Bio

Co-organizer: Suzhou Biomedical Industrial Park (BioBAY)

Conference venue: Shizun Hotel, Dushu Lake, Suzhou

(No. 299 Qiyue Street, Suzhou Industrial Park, Suzhou City, Jiangsu Province)

Figure Microfluidic Nano participates in the 6th Nucleic Acid Vaccine Conference

Figure

Lipid nanoparticles (LNPs), including various lipid delivery platforms, such as liposomes, nanostructured lipid carriers (NLCs) and solid lipid nanoparticles (SLNs), are important for proteins and amino acid antigens. The delivery of antigens is crucial. They ensure that protein or nucleic acid antigens are released into needed organs in the body and prevent uptake by the mononuclear phagocyte system (MPS).

When LNPs are used to deliver DNA or RNA molecules, two methods are usually commonly used-in situ encapsulation or post-encapsulation. The former attempts to add dna or rna to the formation of nanoparticles. The disadvantage is poor encapsulation efficiency and potential reduction in release rates that will offset the rapid response nature of the vaccine. In addition, due to stability and scalability limitations, storing these DNA/RNA vaccines may not be feasible, affecting pandemic preparedness. The latter allows the nanoparticle delivery system to be manufactured and stored separately from the target DNA/RNA, and then combined before vaccination. This two-step approach is a good alternative and ideal way to deal with a pandemic situation because LNPs can be stored and only DNA/RNA production is required after the pandemic begins.

The production of lipid nanoparticles with an average size of approximately 100 nanometers is critical for both transport through the body and sterile filtration.

How does the microfluidic nano-homogenizer supplied by microfluidic nano-supply play a role in the preparation of lipid nanoparticles?

There are many different techniques for the preparation of lipid nanoparticles. The more common techniques are demonstrated in the following five-step process:

Step 1: Dissolve the phospholipid, carrier oil and any hydrophobic active substances in the solvent. The solvent is then removed by evaporation-either by rotary evaporation on a laboratory scale or spray drying on a production scale.

Steps 2 and 3: Add buffer to the precipitate produced in step 1, and heat and vortex to hydrate the phospholipids.

Step 4: Add antigen (or other hydrophilic active substance) to the solution, thereby creating large multilayer vesicles (MLVs).

Step 5: mlv is processed through a microjet nanohomogenizer to reduce its size to small monolayer vesicles.

Figure General steps of applying microfluidic technology to prepare lipid nanoparticles

Here is a recent process improvement to this classic method. If the carrier oil is liquid or soluble in water, there is no need to create a solid solution of the phospholipid and carrier oil. These ingredients can simply be mixed together and added to the aqueous phase, creating a premix before processing using a microjet nanohomogenizer.

In addition, if these antigens can be adsorbed to the surface of LNPs, then adding hydrophilic antigens downstream of LNP production would be effective.

There are other methods of creating LNPs using solvent precipitation methods that are only suitable for small-scale production. Microfluidic nano can help shift technology from solvent precipitation methods to scalable cgmp-validated production methods.

Advantages of microfluidics in the preparation of lipid nanoparticles:

linearly scalable results from laboratory to production

enable the production of large batches of products on a scale of thousands of liters.

High shear treatment effectively reduces the size of the particles.

Uniform processing, small and narrow particle size distribution

. cGMP approved technologyThe

ability to process samples with various lipid concentrations does

not require the use of solvents

In addition, microfluidic nano supply 1) high-pressure microfluidic synthesizer, dual pumps and dual pipelines, supports simultaneous proportional injection of water and oil phases. While mixing, microjet nano homogenization is carried out to complete the process of mixing and nanometer particle size in one step. 2) nCS1 microfluidic nano particle size analyzer uses microfluidic Coulter resistance pulse technology to avoid secondary conversion errors in optical particle size detection equipment. The resistance signal is directly proportional to the particle volume, which can detect lipid nanoparticles with higher resolution. The particle size and concentration.

For more information on the high-pressure microfluidic synthesis instrument, please refer to:

Genizer High-pressure Cross-injection microfluidic mixing homogenization instrument

For more information on the characteristics of the microfluidic nanoparticle particle size and concentration measurement, please refer to:

nCS1 microfluidic nanoparticle size analyzer is used for LNP lipid nanoparticle size and concentration measurement

微流纳米Vic